$416.42
5.121.24%
al cierre: Nov 13, 4:00 PM EST
$416.42
N/A
After hour: 4:02 PM EST
West Pharmaceutical Services rose 56.2% from $266.66 to $416.42, ahead of the S&P 500's +12.3%. Its worst day was Jul 24 (−7.7%), and its low came Feb 3 at $230.95.
Nov 13, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
West Pharmaceutical Services shares rose 5.2%, while the S&P 500 rose 1.0%.
+5.2% · S&P 500 +1.0%
West Pharmaceutical Services shares fell 7.0%, while the S&P 500 fell 0.1%.
−7.0% · S&P 500 −0.1%
Story events cover the past 12 months · Times ET
West Pharmaceutical Services closed at its lowest level of the year, 13.4% below where the year started.
−2.8% · S&P 500 −0.8%
EPS of $2.04 beat the $1.83 estimate on $805.0M revenue (est. $794.6M); FY revenue guidance of $3.2B–$3.3B against the $3.2B consensus.
−1.0% · S&P 500 −1.5%
West Pharmaceutical Services shares fell 5.7%, while the S&P 500 fell 0.2%.
−5.7% · S&P 500 −0.2%
EPS of $2.13 beat the $1.68 estimate on $844.9M revenue (est. $779.2M); Q2 revenue guidance of $830.0M–$850.0M against the $818.7M consensus.
+12.9%, the year's best day, on 3M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $2.37 beat the $2.08 estimate on $872.3M revenue (est. $838.0M); FY revenue guidance of $3.3B–$3.4B against the $3.3B consensus.
−0.8% · S&P 500 −1.2%
EPS of $2.66 beat the $2.19 estimate on $874.5M revenue (est. $826.4M); Q4 revenue guidance of $820.0M–$830.0M against the $827.3M consensus.
+3.2% · S&P 500 −0.4%
Where it ended: a close of $416.42 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $2.28, revenue est. $825.2M).
As of the Nov 13, 2026 close
Replay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for WST and SPY from Benzinga historical bars. Not investment advice.